Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer

NCT06809140 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

47

Enrollment

OTHER

Sponsor class

Conditions

Muscle Invasive Bladder Urothelial Carcinoma

Interventions

DRUG: Enfortumab vedotin
DRUG: Pembrolizumab

Sponsor

Matthew Galsky

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]